Page last updated: 2024-12-06

benoxaprofen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Benoxaprofen is a nonsteroidal anti-inflammatory drug (NSAID) that was developed in the 1970s. It was initially marketed as an analgesic and anti-inflammatory agent for the treatment of rheumatoid arthritis and osteoarthritis. However, its use was discontinued in the late 1980s due to reports of serious side effects, including liver toxicity. Benoxaprofen was synthesized from 2-chloro-4-nitrobenzoic acid through a multi-step process involving acylation, reduction, and halogenation reactions. Its mechanism of action is similar to that of other NSAIDs, involving the inhibition of cyclooxygenase (COX) enzymes, which are involved in the production of prostaglandins, mediators of inflammation and pain. The drug's potency and efficacy were initially considered promising, but its association with severe adverse events, including hepatotoxicity, led to its withdrawal from the market. Although no longer used clinically, benoxaprofen continues to be studied for its pharmacological properties and to understand the mechanisms underlying its hepatotoxicity. This research aims to improve our understanding of drug-induced liver injury and develop strategies to minimize the risk of such adverse events.'

4-phenylcyclohexene: RN in Chemline for cpd without designation of unsaturation: 31017-40-0 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

benoxaprofen: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

benoxaprofen : A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID21096
CHEMBL ID3185227
MeSH IDM0058178
PubMed CID39941
CHEMBL ID340978
CHEBI ID76114
SCHEMBL ID24413
MeSH IDM0058178

Synonyms (112)

Synonym
4-phenylcyclohexene
benzene, 3-cyclohexen-1-yl-
brn 1930089
3-cyclohexen-1-ylbenzene
cyclohex-3-en-1-ylbenzene
4-phenyl-1-cyclohexene
P1445
4994-16-5
NCGC00256873-01
dtxcid7027176
dtxsid9047176 ,
cas-4994-16-5
tox21_302516
cw63r89ow9 ,
unii-cw63r89ow9
4-05-00-01558 (beilstein handbook reference)
FT-0635503
AKOS025295376
XWCWNUSFQVJNDI-UHFFFAOYSA-N
3-cyclohexen-1-ylbenzene #
CHEMBL3185227
3-cyclohexen-1-ylbenzene, aldrichcpr
mfcd00049188
4-phenyl-1-cyclohexene, analytical reference material
AS-57755
(cyclohex-3-en-1-yl)benzene
4-phenyl-1-cyclohexene 100 microg/ml in cyclohexane
1,2,3,6-tetrahydro-1,1'-biphenyl
cyclohex-3-enylbenzene
Q27275855
T72524
CS-0453050
SY052272
67434-14-4
2-[2-(4-chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid
2-(2-(4-chlorophenyl)-1,3-benzoxazol-5-yl)propanoic acid
oraflex
D03080
oraflex (tn)
benoxaprofen (usan/inn)
uniprofen
5-benzoxazoleacetic acid, 2-(4-chlorophenyl)-alpha-methyl, (+-)-
benoxaprofenum [inn-latin]
benoxaprofeno [inn-spanish]
benoxaprofen [usan:inn:ban]
benoxaprofene [inn-french]
(+-)-2-(p-chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid
brn 1085080
lilly 90459
lrcl 3794
einecs 257-069-7
nsc 299582
nsc-299582
coxigon
benoxaprofen
inflamid
opren
2-(p-chlorophenyl)-.alpha.-methyl-5-benzoxazoleacetic acid
nsc299582
compound 90459
51234-28-7
5-benzoxazoleacetic acid, 2-(4-chlorophenyl)-.alpha.-methyl-
2-(4-chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid
DB04812
dl-benoxaprofen
(1)-2-(4-chlorophenyl)benzoxazole-5-propionic acid
(+/-)-benoxaprofen
2-(p-chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid
C90147
compd 90459
CHEMBL340978
chebi:76114 ,
FT-0662523
(+-)-2-(4-chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid
benoxaprofenum
benoxaprofeno
17szx404im ,
unii-17szx404im
einecs 266-692-3
benoxaprofene
(+-)-benoxaprofen
1329840-53-0
benoxaprofen-13c,d3
SCHEMBL24413
benoxaprofen [mi]
benoxaprofen [jan]
5-benzoxazoleacetic acid, 2-(4-chlorophenyl)-.alpha.-methyl, (+/-)-
benoxaprofen [usan]
compound-90459
benoxaprofen [mart.]
benoxaprofen [who-dd]
(+/-)-2-(p-chlorophenyl)-.alpha.-methyl-5-benzoxazoleacetic acid
benoxaprofen [inn]
MITFXPHMIHQXPI-UHFFFAOYSA-N
2-[2-(4-chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid #
5-benzoxazoleacetic acid, 2-(4-chlorophenyl)-.alpha.-methyl, (.+/-.)-
2-(4-chlorophenyl)-.alpha.-methyl-5-benzoxazoleacetic acid
(.+/-.)-2-(p-chlorophenyl)-.alpha.-methyl-5-benzoxazoleacetic acid
bdbm50088388
DTXSID4022650
2-(2-(4-chlorophenyl)benzo[d]oxazol-5-yl)propanoic acid
FT-0662524
Q420082
A905882
(rs)-benoxaprofen
EN300-18567267
HY-13568
CS-0007198
SY331468
mfcd00866099
2-[2-(4-chlorophenyl)-5-benzoxazolyl]propanoic acid
AKOS040744412

Research Excerpts

Toxicity

The study was made of adverse dermatological reactions to the non-steroidal anti-inflammatory agent. Discontinuation due to lack of efficacy or adverse effects was substantially lower for benoxaprofen than for aspirin or ibuprofen.

ExcerptReferenceRelevance
" The toxic hydrocarbons are also inducers of cytochrome P448-mediated mixed function oxidases."( Benoxaprofen suppression of polychlorinated biphenyl toxicity without alteration of mixed function oxidase function.
Muschick, H; Rifkind, AB,
)
0.13
" These results support the hypothesis that the immunotoxicity caused by halogenated and polycyclic aromatic hydrocarbons is a consequence of activation of the Ah gene complex and suggests that this toxic effect can be initiated by any Ah receptor ligand."( Correlations between polychlorinated biphenyl immunotoxicity, the aromatic hydrocarbon locus, and liver microsomal enzyme induction in C57BL/6 and DBA/2 mice.
Antrim, L; Kaminsky, LS; Silkworth, JB, 1984
)
0.27
" In addition to gastrointestinal intolerance, photosensitivity and onycholysis are the most frequent adverse effects encountered."( Pharmacology, clinical efficacy, and adverse effects of the nonsteroidal anti-inflammatory agent benoxaprofen.
Dahl, SL; Ward, JR,
)
0.13
"A study was made of adverse dermatological reactions to the non-steroidal anti-inflammatory agent benoxaprofen."( Side effects of benoxaprofen.
Daymond, T; Diffey, B; Hindson, C; Lawlor, F, 1982
)
0.26
" Discontinuation due to lack of efficacy or adverse effects was substantially lower for benoxaprofen than for aspirin or ibuprofen."( An update on long-term efficacy and safety with benoxaprofen.
Mikulaschek, WM, 1982
)
0.26
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43

Pharmacokinetics

The pharmacokinetic profile of benoxaprofene, administered in a single oral dose of 600 mg, has been determined comparatively in 5 normal subjects and 15 patients with renal insufficiency (five of whom were on chronic hemodialysis) The higher benoxAProfen concentrations and the long elimination half-life show evidence of accumulation in the elderly.

ExcerptReferenceRelevance
" The plasma levels of the drug after oral administration of a solution best fitted a 2-compartment open pharmacokinetic model, whereas the levels after the solid dosage forms more appropriately fitted the simple 1-compartment open model."( Pharmacokinetic studies of benoxaprofen after therapeutic doses with a review of related pharmacokinetic and metabolic studies.
Carmichael, RH; Nash, JF; Ridolfo, AS; Spradlin, CT, 1980
)
0.26
"The pharmacokinetic profile of benoxaprofen given as a single oral dose of 600 mg was determined comparatively in 5 healthy volunteers and in 15 patients with various degrees of renal insufficiency (5 of whom were undergoing maintenance hemodialysis)."( Pharmacokinetic profile of benoxaprofen in subjects with normal and impaired renal function, prediction of multiple-dose kinetics.
Brogard, JM; Comte, F; Madon, M; Spach, MO, 1982
)
0.26
" This resulted in a means half-life of 147."( The pharmacokinetics of benoxaprofen in elderly subjects.
Hamdy, RC; Koch, IM; Murnane, B; Perera, N; Woodcock, K, 1982
)
0.26
" The higher benoxaprofen concentrations and the long elimination half-life show evidence of accumulation in the elderly, probably due to several causes, including poor bowel motility and decreased renal clearance common with increasing age."( Pharmacokinetic studies of benoxaprofen in geriatric patients.
Kamal, A; Koch, IM, 1982
)
0.26
"The pharmacokinetic profile of benoxaprofene, administered in a single oral dose of 600 mg, has been determined comparatively in 5 normal subjects and 15 patients with renal insufficiency (five of whom were on chronic hemodialysis)."( [Benoxaprofene: pharmacokinetic profile in the normal subject and patients with renal insufficiency; evaluation of anticipated serum levels].
Audhuy, B; Brogard, JM; Spach, MO, 1981
)
0.26
" The development of NSAIDs having safer therapeutic profile depends on the better understanding of their mechanisms, physicochemical and pharmacokinetic properties."( Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
Kumar, M; Sinha, VR; Thareja, S, 2012
)
0.38

Bioavailability

Azapropazone has been found to be well absorbed, and benoxaprofen and fenclofenac somewhat more slowly. For the latter two drugs their low rate of absorption might also be a factor in their reduced ulcerogenicity.

ExcerptReferenceRelevance
" Benoxaprofen was well absorbed after oral administration of doses of 1 to 10 mg/kg in all six species."( Disposition and metabolism of benoxaprofen in laboratory animals and man.
Chatfield, DH; Green, JN, 1978
)
0.26
"A study of the effect of crystal size on the bioavailability of benoxaprofen, 2-[4-chlorophenyl]-alpha-methyl-5-benzoxazoleacetic acid, in man is reported."( The effect of crystal size on the bioavailability of benoxaprofen: studies utilizing deuterium labeled drug.
Carmichael, RH; Ridolfo, AS; Thompkins, L; Wolen, RL; Ziege, EA, 1979
)
0.26
" Azapropazone has been found to be well absorbed, and benoxaprofen and fenclofenac somewhat more slowly, so for the latter two drugs their low rate of absorption might also be a factor in their reduced ulcerogenicity."( Structural damage and changes in eicosanoid metabolites in the gastric mucosa of rats and pigs induced by anti-inflammatory drugs of varying ulcerogenicity.
Rainsford, KD, 1986
)
0.27
"Studies were performed in fasted rats to establish if the propensity of 4 non-steroidal anti-inflammatory (NSAI) drugs to elicit varying degrees of gastric mucosal damage following oral administration is related to their rate of absorption by the mucosal and subsequent inhibitory effects on prostaglandin (PG) production in vivo."( Comparative effects of some non-steroidal anti-inflammatory drugs on the ultrastructural integrity and prostaglandin levels in the rat gastric mucosa: relationship to drug uptake.
Fox, SA; Osborne, DJ; Rainsford, KD, 1984
)
0.27
"The bioavailability of a single 300 mg dose of benoxaprofen was compared after rectal and oral administration in 5 subjects."( The pharmacokinetics and acceptability of benoxaprofen following rectal administration.
Glynne, A; Jones, RW; Waugh, AE; Wild, RN; Woodage, TJ, 1980
)
0.26

Dosage Studied

The safety and efficacy of benoxaprofen (300 or 600 mg) and indomethacin 75 to 150 mg) were compared in optimum dosage levels for 91 patients with rheumatoid arthritis or osteoarthritis. Computerized thermography showed that, at a dosage of 600 mg daily, benoxAProfen had a significant antiinflammatory effect.

ExcerptRelevanceReference
" Female B6C3F1 mice were dosed with VCH (6 mmol/kg/day, ip) or 4PC (3 or 6 mmol/kg/day, ip) daily for 30 days."( Differential ovotoxicity of 4-vinylcyclohexene and its analog, 4-phenylcyclohexene.
Hooser, SB; Parola, LR; Sipes, IG; Van Ert, MD, 1993
)
0.29
"A single daily dose of 600 mg of henoxaprofen has been shown to be more effective than a previously reported dosage regime in patients with rheumatoid arthritis."( Treatment of rheumatoid arthritis with a single daily dose of benoxaprofen.
Huskisson, EC; Scott, J, 1979
)
0.26
" In this study, four NSAIDs were investigated for their phototoxicity potential in human volunteers using an oral dosing protocol."( Photosensitizing potential of certain nonsteroidal anti-inflammatory agents.
Kaidbey, KH; Mitchell, FN, 1989
)
0.28
" The ratio of the glucuronides of (S)-benoxaprofen to that of (R)-benoxaprofen in rhesus monkey urine varied between individual animals and appeared to change through time as dosing continued."( Species-dependent enantioselective glucuronidation of three 2-arylpropionic acids. Naproxen, ibuprofen, and benoxaprofen.
Dulik, DM; el Mouelhi, M; Fenselau, C; Ruelius, HW,
)
0.13
" These results provide a preliminary indication that solid-state NMR spectroscopy is a useful technique for the investigation of drug polymorphs and drugs in their dosage forms."( Analysis of solid-state Carbon-13 NMR spectra of polymorphs (benoxaprofen and nabilone) and pseudopolymorphs (cefazolin).
Byrn, SR; Frye, J; Gray, G; Pfeiffer, RR, 1985
)
0.27
" Alterations in L/P ratio preceded the release of cytosolic ALT and at 4 h a well defined dose-response relationship existed between the benoxaprofen concentration and the observed increases in the L/P ratio and ALT release."( Benoxaprofen induced toxicity in isolated rat hepatocytes.
Cassidy, MR; Drew, R; Knights, KM, 1986
)
0.27
") failed to elicit mucosal damage either ultrastructurally or even visually up to 23 h after dosing and did not affect the content of PG's even though the drug was present in the mucosa in sufficient concentration to elicit reduction in prostaglandin synthesis in vitro."( Comparative effects of some non-steroidal anti-inflammatory drugs on the ultrastructural integrity and prostaglandin levels in the rat gastric mucosa: relationship to drug uptake.
Fox, SA; Osborne, DJ; Rainsford, KD, 1984
)
0.27
" Once daily dosing of 300-600 mg is effective for many patients."( Pharmacology, clinical efficacy, and adverse effects of the nonsteroidal anti-inflammatory agent benoxaprofen.
Dahl, SL; Ward, JR,
)
0.13
" The non-steroid antirheumatic benoxaprofen was used alone in a dosage of a 1 x 600 mg tablet daily."( [Benoxaprofen in the treatment of spondylosis and spondylarthrosis (author's transl)].
Hevelke, G; Schilling, E, 1981
)
0.26
" These findings show that benoxaprofen is a potent phototoxic drug and that the manufacturers' recommended dosage of 600 mg daily is associated with an unacceptable incidence of side effects in the elderly."( Benoxaprofen: side-effect profile in 300 patients.
Cardoe, N; Halsey, JP, 1982
)
0.26
" The plasma levels of the drug after oral administration of a solution best fitted a 2-compartment open pharmacokinetic model, whereas the levels after the solid dosage forms more appropriately fitted the simple 1-compartment open model."( Pharmacokinetic studies of benoxaprofen after therapeutic doses with a review of related pharmacokinetic and metabolic studies.
Carmichael, RH; Nash, JF; Ridolfo, AS; Spradlin, CT, 1980
)
0.26
" At the given dosage (mg/kg/day), benoxaprofen (10), aspirin (25), and indomethacin (3) inhibited the hindpaw swelling and development of anti-type II collagen antibodies in collagen-treated rats."( Effects of benoxaprofen on the inflammatory, humoral and cellular components of type II collagen-induced arthritis in rats.
Nanda, S; Phadke, K, 1982
)
0.26
" Computerized thermography showed that, at a dosage of 600 mg daily, benoxaprofen had a significant antiinflammatory effect; this observation was confirmed by the comparison with indomethacin."( Benoxaprofen--dose-range studies using quantitative thermography.
Bacon, PA; Davies, J; Ring, FJ, 1980
)
0.26
"The safety and efficacy of benoxaprofen (300 or 600 mg) and indomethacin 75 to 150 mg) were compared in optimum dosage levels for 91 patients with rheumatoid arthritis or osteoarthritis."( Crossover comparison of benoxaprofen and indomethacin in rheumatoid arthritis and osteoarthritis.
Chodock, AL, 1982
)
0.26
" A dosage nomogram was derived from which a dose one half of the normal maintenance dose was suggested for patients with severe renal failure."( Benoxaprofen kinetics in renal impairment.
Aronoff, GR; DeSante, KA; Nash, JF; Ozawa, T; Ridolfo, AS, 1982
)
0.26
" It appears advisable to reduce the dosage by half only in patients with a Cr clearance of less than 10-20 ml/min/1."( [Benoxaprofene: pharmacokinetic profile in the normal subject and patients with renal insufficiency; evaluation of anticipated serum levels].
Audhuy, B; Brogard, JM; Spach, MO, 1981
)
0.26
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
"Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state."( Relevance of Half-Life in Drug Design.
Beaumont, K; Di, L; Maurer, TS; Smith, DA, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (8)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitorA lipoxygenase inhibitor that interferes with the action of arachidonate 5-lipoxygenase (EC 1.13.11.34).
antipyreticA drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
protein kinase C agonistAn agonist that selectively binds to and activates a protein kinase C receptor
hepatotoxic agentA role played by a chemical compound exihibiting itself through the ability to induce damage to the liver in animals.
antipsoriaticA drug used to treat psoriasis.
nephrotoxinA poison that interferes with the function of the kidneys.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
1,3-benzoxazolesCompounds based on a fused 1,3-oxazole and benzene bicyclic ring skeleton.
monocarboxylic acidAn oxoacid containing a single carboxy group.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency72.65380.000714.592883.7951AID1259392
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency76.95880.003041.611522,387.1992AID1159553
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency24.33650.001530.607315,848.9004AID1224841
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency69.16660.057821.109761.2679AID1159528
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)99.10000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)139.35000.11007.190310.0000AID1209455; AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID189987Gastrointestinal tolerability was evaluated under chronic conditions, in rats. The ulcerogenic dose was reported1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Nonsteroidal antiinflammatory agents. 14. Synthesis and pharmacological profile of 6-chloro-5-(cyclopentylmethyl)indan-1-carboxylic acid.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID193991Gastrointestinal tolerability was evaluated in rats and compound dose that causes lethality was reported1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Nonsteroidal antiinflammatory agents. 14. Synthesis and pharmacological profile of 6-chloro-5-(cyclopentylmethyl)indan-1-carboxylic acid.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1134154Antiinflammatory activity in adrenalectomized rat assessed as inhibition of carrageenan-induced paw edema administered orally 1 hr prior to challenge measured 2.5 hrs post challenge1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Synthesis and antiinflammatory activity of some 2-aryl-6-benzoxazoleacetic acid derivatives.
AID1134156Toxicity in po dosed rat1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Synthesis and antiinflammatory activity of some 2-aryl-6-benzoxazoleacetic acid derivatives.
AID677462Dissociation constant, pKa of the compound2012European journal of medicinal chemistry, Jul, Volume: 53Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
AID173208Gastrointestinal tolerability was evaluated in rats and amount blood loss was reported1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Nonsteroidal antiinflammatory agents. 14. Synthesis and pharmacological profile of 6-chloro-5-(cyclopentylmethyl)indan-1-carboxylic acid.
AID178648Antiinflammatory activity was evaluated in an carrageenan edema (acute inflammation) test, after administering compound orally in rats; 15-301984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Nonsteroidal antiinflammatory agents. 14. Synthesis and pharmacological profile of 6-chloro-5-(cyclopentylmethyl)indan-1-carboxylic acid.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID177359Antiinflammatory activity was evaluated in an adjuvant arthritis (subchronic inflammation) test after administering compound orally in rats1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Nonsteroidal antiinflammatory agents. 14. Synthesis and pharmacological profile of 6-chloro-5-(cyclopentylmethyl)indan-1-carboxylic acid.
AID1367809Terminal half life in human2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Relevance of Half-Life in Drug Design.
AID1134148Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered as two doses 3 and 0.5 hr prior to challenge measured 2.5 hrs post challenge1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Synthesis and antiinflammatory activity of some 2-aryl-6-benzoxazoleacetic acid derivatives.
AID1134155Antiinflammatory activity in adrenalectomized rat assessed as inhibition of carrageenan-induced paw edema administered orally 1 hr prior to challenge measured 5 hrs post challenge1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Synthesis and antiinflammatory activity of some 2-aryl-6-benzoxazoleacetic acid derivatives.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID189984Gastrointestinal tolerability was evaluated under acute conditions, in rats. The ulcerogenic dose was reported1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Nonsteroidal antiinflammatory agents. 14. Synthesis and pharmacological profile of 6-chloro-5-(cyclopentylmethyl)indan-1-carboxylic acid.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (323)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990281 (87.00)18.7374
1990's18 (5.57)18.2507
2000's12 (3.72)29.6817
2010's12 (3.72)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.76 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index44.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials42 (12.65%)5.53%
Reviews0 (0.00%)6.00%
Reviews17 (5.12%)6.00%
Case Studies1 (14.29%)4.05%
Case Studies33 (9.94%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
Other240 (72.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]